EMA to cut activities as it forecasts loss of 30% of staff
pharmafile | August 2, 2018 | News story | Medical Communications, Research and Development | EMA, London, UK, amsterdam, brexit, disruption, staff
The European Medicines Agency is set to enact temporary cuts in activities as it prepares for significant disruption in the wake of Brexit.
The Agency announced on Wednesday that it now expects to lose 30% of its staff as it makes the move from London to Amsterdam.
While the EMA had previously predicted that around 19% of its staff would leave, the European agency upped the figure by 11% as it revealed that employees who do not want to make the move to the Dutch capital have already begun to depart.
The medicines regulator noted that a further 135 short-term contract staff will not be allowed to continue to work in the Netherlands due to Dutch employment laws. As such, the agency which currently employs around 900 people, expects a significant loss in numbers.
Thus in preparation for the far reaching disruption, the EMA have announced that they will scale back additional activities until 2019, as it trains staff who will be re-assigned to new duties.
The areas impacted include collaboration at an international level, the development and revision of guidelines, organisation and attendance at stakeholder meetings and clinical data publication. The plan will be implemented on October 1st at the latest.
The news comes as it was announced that the medicines agency is being taken to court over a £500 million unpaid rent bill, as it seeks to leave its Canary Wharf premises.
Louis Goss
Related Content
EC approves Pfizer’s Prevenar 20 to protect paediatric patients against pneumococcal disease
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Prevenar 20, …
EMA validates two applications for datopotamab deruxtecan for cancer treatments
AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications …
AstraZeneca’s Voydeya recommended for approval in EU by CHMP
AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European …
